Literature DB >> 8077768

Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro.

C E Weeks1, S J Gibson.   

Abstract

The low-molecular-weight immunomodulator drug candidate, imiquimod (R-837), and its hydroxylated metabolite R-842, induce interferon-alpha (IFN-alpha) in human blood cells in vitro when tested in concentrations of 0.5 microgram/ml or more. The amounts of IFN-alpha found increased with time from 2-6 h of incubation up to 24-48 h, and were dependent on cell number and drug concentration. These two chemicals yielded more IFN-alpha in human peripheral blood mononuclear cell (PBMC) cultures than other known inducers tested in parallel. They also induced detectable amounts of interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor-alpha in human PBMC cultures in vitro.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077768     DOI: 10.1089/jir.1994.14.81

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  14 in total

Review 1.  Discovery of immunopotentiatory drugs: current and future strategies.

Authors:  J Rhodes
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

Review 2.  Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.

Authors:  M Afshar; A D Martinez; R L Gallo; T R Hata
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-06-01       Impact factor: 6.166

3.  Keloids: pathogenesis, clinical features, and management.

Authors:  Chuma J Chike-Obi; Patrick D Cole; Anthony E Brissett
Journal:  Semin Plast Surg       Date:  2009-08       Impact factor: 2.314

Review 4.  Modulation of antitumor responses by dendritic cells.

Authors:  Johannes Vieweg; Andrew Jackson
Journal:  Springer Semin Immunopathol       Date:  2005-01

5.  Elimination of duck hepatitis B virus RNA-containing capsids in duck interferon-alpha-treated hepatocytes.

Authors:  U Schultz; J Summers; P Staeheli; F V Chisari
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  A new role for microRNAs, as ligands of Toll-like receptors.

Authors:  Muller Fabbri; Alessio Paone; Federica Calore; Roberta Galli; Carlo M Croce
Journal:  RNA Biol       Date:  2013-01-07       Impact factor: 4.652

Review 7.  Topical imiquimod: a review of its use in genital warts.

Authors:  C M Perry; H M Lamb
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

8.  Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.

Authors:  Laura M Fahey; Adam B Raff; Diane M Da Silva; W Martin Kast
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

9.  Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele).

Authors:  J Moisan; W Wojciechowski; C Guilbault; C Lachance; S Di Marco; E Skamene; G Matlashewski; D Radzioch
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells.

Authors:  Rachael A Clark; Susan J Huang; George F Murphy; Ilse G Mollet; Dirkjan Hijnen; Manoj Muthukuru; Carl F Schanbacher; Vonetta Edwards; Danielle M Miller; Jenny E Kim; Jo Lambert; Thomas S Kupper
Journal:  J Exp Med       Date:  2008-09-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.